Please wait while the formulary information is being retrieved.
ABECMA (idecabtagene vicleucel)
- multiple myeloma
300x10exp6 to 460x10exp6 cell intravenous suspension
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- None
Contraindicated
- Neutropenic disorder
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Cytomegalovirus disease
- Reactivation of hepatitis B
ABECMA (idecabtagene vicleucel)
- multiple myeloma
- Anemia
- Cytokine release syndrome
- Leukopenia
- Lymphopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Anorexia
- Cough
- Diarrhea
- Edema
- Encephalopathy
- Fatigue
- Fever
- Headache disorder
- Hypogammaglobulinemia
- Musculoskeletal pain
- Nausea
- Upper respiratory infection
- Viral infection
More Frequent
Severe
Less Severe
- Aphasia
- Atrial fibrillation
- Bacterial infection
- Cardiomyopathy
- Fungal infection
- Gastrointestinal hemorrhage
- Hemophagocytic lymphohistiocytosis
- Hypersensitivity drug reaction
- Hypertension
- Hyponatremia
- Hypophosphatemia
- Hypotension
- Hypoxia
- Increased risk of bleeding due to coagulation disorder
- Infection
- Macrophage activation syndrome
- Pneumonia
- Pulmonary edema
- Renal failure
- Seizure disorder
- Sepsis
- Thrombotic disorder
- Ataxia
- Chills
- Constipation
- Delirium
- Dizziness
- Dry eye
- Dry skin
- Dyspnea
- Insomnia
- Pain in oropharynx
- Peripheral neuropathy
- Prolonged activated partial thromboplastin time
- Skin rash
- Symptoms of anxiety
- Tachycardia
- Tremor
- Weight loss
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Cerebral edema
- Cytomegalovirus disease
- Myelitis
- Parkinsonism
- Pneumocystis jirovecii pneumonia
- Reactivation of hepatitis B
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Idecabtagene vicleucel
Safety and effectiveness not established in pediatric patients < 18 years.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients < 18 years.
Idecabtagene Vicleucel
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Iecabtagene Vicleucel
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may cause serious (even fatal) reactions (cytokine release syndrome-CRS, hemophagocytic lymphohistiocytosis-HLH/macrophage activation syndrome-MAS). Careful monitoring and prompt treatment may decrease your risk. Before treatment with this medication, tell your doctor your medical history, especially of any current/recent infection.<br /><br />Tell your doctor right away if you have any symptoms such as high fever, trouble breathing, chills/shaking chills, severe nausea/vomiting/diarrhea, severe muscle/joint pain, very low blood pressure, dizziness/lightheadedness, or signs of kidney problems (such as change in the amount of urine). Serious nerve problems can occur after treatment with idecabtagene vicleucel. Tell your doctor right away if you have drowsiness, seizure(s), mental/mood changes (such as confusion, anxiety, memory loss), or trouble with reading, writing, speaking, or understanding.<br /><br /> This product may cause a severe decrease in your blood cells, which lowers your ability to fight infections and increases the risk of anemia/bleeding problems. You may be more likely to get a serious (rarely fatal) infection and any infection you have may get worse. Tell your doctor right away if you have signs of infection (such as a sore throat that doesn't go away, fever, chills, cough), easy or unusual bruising/bleeding, or unusual tiredness.<br /><br /> For patients to receive this medication, all doctors, pharmacists, and patients must agree to, understand, and carefully follow the requirements of the Abecma REMS Program. These requirements apply in the United States. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
| Multiple myeloma | |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| 0-9 | A-Z |
|---|---|
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
Formulary Reference Tool